Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Trial ID or NCT#

NCT01304303

Status

not recruiting iconNOT RECRUITING

Purpose

Phase I study of SPARC1023 alone and in combination with carboplatin

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Age ≥18 years - ECOG Performance Status ≤ 1. - Estimated life expectancy of at least 12-weeks; - Measurable disease as per RECIST guideline (Version 1.1);
Exclusion Criteria:
  1. - Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer - Known hypersensitivity to the study drugs - Treatment with any anti-cancer agents within 28 days of study entry - Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy
View All Criteria
Show Less

Investigator(s)

George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov